Valrubicin (N-trifluoroacetyladriamycin-14-valerate), a semisynthetic analog of the anthra-cycline doxorubicin, is a cytotoxic agent.
VALSTAR is indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.
Media Articles Related to Valstar (Valrubicin)
Analyses finds no strong association between use of diabetes drug pioglitazone and increased risk of bladder cancer
Source: Cancer / Oncology News From Medical News Today [2015.07.22]
Although some previous studies have suggested an increased risk of bladder cancer with use of the diabetes drug pioglitazone, analyses that included nearly 200,000 patients found no statistically...
Study Refutes Notion That Diabetes Drug Actos Raises Bladder Cancer Risk
Source: MedicineNet Bladder Cancer Specialty [2015.07.22]
Title: Study Refutes Notion That Diabetes Drug Actos Raises Bladder Cancer Risk
Category: Health News
Created: 7/21/2015 12:00:00 AM
Last Editorial Review: 7/22/2015 12:00:00 AM
Pioglitazone Use Not Linked to Bladder Cancer at 10 Years
Source: Medscape Diabetes & Endocrinology Headlines [2015.07.21]
Two database analyses find no association between use of pioglitazone and bladder cancer at 10 years, but some data suggest a possible link to pancreatic and prostate cancer.
Medscape Medical News
Long-term survival rates satisfactory for bladder cancer patients treated with robotic surgery
Source: Urology / Nephrology News From Medical News Today [2015.06.30]
In the largest multi-institutional study to date, patients diagnosed with bladder cancer and treated with robot-assisted surgery experienced similar results to those who underwent a traditional...
Persistent UTI Symptoms May Signal Bladder Cancer
Source: MedicineNet Bladder Cancer Specialty [2015.05.22]
Title: Persistent UTI Symptoms May Signal Bladder Cancer
Category: Health News
Created: 5/22/2015 12:00:00 AM
Last Editorial Review: 5/22/2015 12:00:00 AM
Published Studies Related to Valstar (Valrubicin)
Factors affecting valrubicin response in patients with bacillus Calmette-Guerin-refractory bladder carcinoma in situ. [2011.05]
OBJECTIVE: Patients with bacillus Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the bladder are candidates for intravesical (IVe) valrubicin. This post-hoc analysis of data from the pivotal phase 3, prospective, open-label study of valrubicin evaluated the effects of patient characteristics and past treatments on the response to valrubicin... CONCLUSIONS: In these patients with BCG-refractory CIS, complete responders to valrubicin did not differ significantly from partial or nonresponders in the number of prior courses or instillations. The results suggest that therapy with valrubicin may be considered in appropriate candidates who have not responded to prior therapies. Cystectomy should be reconsidered when valrubicin treatment fails.
Topical application of valrubicin has a beneficial effect on developing skin tumors. [2010.08]
Valrubicin is a second generation anthracycline characterized by an excellent safety profile presenting no skin toxicity or necrosis upon contact...
Valrubicin in a topical formulation treats psoriasis in a xenograft transplantation model. [2010.02]
Valrubicin is a cytostatic drug currently approved by the American Federal Drug Administration as a trademarked Valstar sterile solution for the treatment of bladder cancer. Valrubicin has shown an excellent therapeutic potential with minimal toxicity.
Clinical Trials Related to Valstar (Valrubicin)
Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma [Recruiting]
The purpose of this study is to learn more about how well the drug valrubicin (VALSTARŪ)
works to help treat the patient's cancer when administered through a nephrostomy tube
inserted through their back into their kidney. The study is also being done to determine how
safe and easy it is to tolerate valrubicin at specific dose levels, as well as the way in
which the drug is eliminated from the human body (Pharmacokinetics or PK).
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer [Not yet recruiting]
The use of a designed viral vector that can destroy cancer cells while leaving normal cells
largely unharmed. The virus also stimulates an immunological response by producing a special
factor (GM-CSF) to attract and promote the development of dendritic and T effector cells. It
forms the hypothesis that this regimen may be used for people who have failed current forms
of treatment and are recommended for cystectomy. It is with hope that this novel therapy
will be able to delay or potentially avoid cystectomy for this patient population. Bladder
instillation of this agent causes little long lasting side effects and may drastically
improve the stimulation of the immune system for local cancer cell death as well as
destroying those tumor cells that may have travelled to regional lymph nodes or distant